| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England journal of medicine 389 (4), 335-347, 2023 | 167 | 2023 |
| A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma A Chari, HJ Cho, A Dhadwal, G Morgan, L La, K Zarychta, D Catamero, ... Blood advances 1 (19), 1575-1583, 2017 | 41 | 2017 |
| A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma A Chari, HJ Cho, S Leng, A Dhadwal, G Morgan, L La, K Garcia, C Carter, ... Blood, The Journal of the American Society of Hematology 126 (23), 4226-4226, 2015 | 26 | 2015 |
| Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with … D Dytfeld, B Dhakal, M Agha, S Manier, M Delforge, S Kuppens, S Afifi, ... Blood 138, 1835, 2021 | 17 | 2021 |
| Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab A Chari, T Satta, A Tayal, S Jagannath, HJ Cho, S Parekh, K Lau, ... Blood 126 (23), 3571, 2015 | 16 | 2015 |
| A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma O Van Oekelen, S Parekh, HJ Cho, N Vishnuvardhan, D Madduri, ... Leukemia & lymphoma 61 (9), 2208-2215, 2020 | 15 | 2020 |
| Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab (JNJ-64407564) for the treatment of … SS Mancia, A Farrell, K Louw, E Florendo, E Aronson, K Purcell, ... Blood 138, 1658, 2021 | 14 | 2021 |
| A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin … AJ Ocean, TS Bekaii-Saab, I Chaudhary, R Palmer, PJ Christos, ... Journal of Clinical Oncology 31 (4_suppl), 450-450, 2013 | 13 | 2013 |
| DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: A randomized phase 3 … M Boccadoro, J San-Miguel, K Suzuki, NWCJ Van De Donk, G Cook, ... Blood 140 (Supplement 1), 4630-4632, 2022 | 7 | 2022 |
| A phase II study of pomalidomide, daily low dose oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma A Chari, HJ Cho, S Parekh, K Lau, G Morgan, D Catamero, M Cortes, ... Blood 128 (22), 4520, 2016 | 6 | 2016 |
| Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study … MH Sidiqi, P Corradini, D Purtill, H Einsele, B Dhakal, L Karlin, S Manier, ... Blood 142, 4866, 2023 | 5 | 2023 |
| Optimal supportive care with selinexor improves outcomes in patients with relapsed/refractory multiple myeloma A Chari, E Florendo, IS Mancia, H Cho, D Madduri, S Parekh, J Richter, ... Clinical Lymphoma Myeloma and Leukemia 21 (12), e975-e984, 2021 | 5 | 2021 |
| Randomised, phase 3 study of bortezomib, lenalidomide and dexamethasone followed by ciltacabtagene autoleucel versus bortezomib, lenalidomide and dexamethasone followed by … D Dytfeld, B Dhakal, M Agha, S Manier, M Delforge, S Kuppens, S Afifi, ... British Journal Of Haematology 197, 122-123, 2022 | 2 | 2022 |
| Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma K Osman, A Chari, S Parekh, C Pun, G Morgan, E Florendo, E Chan, ... Blood 128 (22), 3448, 2016 | 2 | 2016 |
| Recapturing disease response: a phase II study of high dose carfilzomib in patients with relapsed or refractory multiple myeloma who have progressed on standard dose carfilzomib A Chari, HJ Cho, S Parekh, K Osman, T Goldstein, G Morgan, L La, ... Blood 126 (23), 3051, 2015 | 2 | 2015 |
| Phase II trial of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma LC Garrot, A Berkenblit, M Goldstein, E Florendo, J Underhill, P Forino, ... Journal of Clinical Oncology 24 (18_suppl), 14103-14103, 2006 | 2 | 2006 |
| Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. LJ Costa, KC Weisel, NWCJ van de Donk, S Sidana, YC Cohen, D Purtill, ... Journal of Clinical Oncology 42 (16_suppl), 7504-7504, 2024 | 1 | 2024 |
| Efficacy and Adverse Events After Ciltacabtagene Autoleucel Treatment in the CARTITUDE-4 As-Treated Population Consisting of Patients With Lenalidomide-Refractory Multiple … I Applewhite, G Elfrink, J Esselmann, C Lonardi, E Florendo, MH Sidiqi ONS 49th Annual Congress, 2024 | 1 | 2024 |
| OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy S Manier, J San-Miguel, B Dhakal, K Yong, J Martinez-Lopez, A Oriol, ... Clinical Lymphoma Myeloma and Leukemia 23, S29-S30, 2023 | 1 | 2023 |
| Incidence and Management of Cranial Nerve Impairments in Patients With Multiple Myeloma Treated With Ciltacabtagene Autoleucel in CARTITUDE Studies L Bennett, S Kruyswijk, S Sidana, E Lee, E Florendo, N van de Donk ONS 49th Annual Congress, 2024 | | 2024 |
